Clinical trials: Moderate-to-severe Psoriasis
Moderate to Severe Chronic Plaque-Type Psoriasis
4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
CAIN457A2304E1 was an extension study to two phase III studies, CAIN457A2304 and CAIN457A2307 (core studies). This extension study planned to collect up to four years of long-term safety, tolerability and efficacy data of…
- Trial name
- NCT01640951
- Testing
- AIN457 150 mg, AIN457 300 mg
- Where
- 111 sites in United States, Austria and 13 more
- Volunteers
- 675 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
ACT-128800 in Psoriasis
This study will assess the efficacy, safety, and tolerability of ACT-128800 in subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT00852670
- Testing
- ACT-128800
- Where
- 14 sites in Austria, France and 3 more
- Volunteers
- 66 people
- Sponsor
- Actelion
Plaque Psoriasis
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06550076
- Testing
- TAK-279
- Where
- 278 sites in United States, Argentina and 18 more
- Volunteers
- 2,099 people
- Sponsor
- Takeda
Plaque Psoriasis
A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy
This is a double-blind, placebo-controlled study in adults with a diagnosis of moderate-to-severe chronic plaque psoriasis to test the efficacy and safety of piclidenoson in this patient population.
- Trial name
- NCT06643260
- Testing
- piclidenoson
- Volunteers
- 705 people
- Sponsor
- Can-Fite BioPharma
Psoriasis
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Psoriasis
This study will examine the safety and efficacy in subjects with moderate to severe psoriasis, as measured by Psoriasis Area and Severity Index(PASI), Body Surface Area (BSA), Dermatology Life Quality Index (DLQI) and other…
- Trial name
- NCT01837420
- Testing
- VB-201 80mg, VB-201 160mg
- Where
- 4 sites in Germany, Israel and 2 more
- Volunteers
- 194 people
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
Psoriasis
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01309737
- Testing
- CP-690,550
- Where
- 94 sites in United States, Canada and 9 more
- Volunteers
- 960 people
- Sponsor
- Pfizer
Psoriasis
Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis
Evaluate psoriasis severity and its psychosocial impact using a novel Patient Reported Outcome (the Simplified Psoriasis Index SPI) at 16 weeks, as well as long-term safety, tolerability and efficacy of secukinumab administered…
- Trial name
- IPSI-PSO (NCT02595970)
- Testing
- Secukinumab
- Where
- 17 sites in France
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: Does ESK-001 reduce the severity of people's psoriasis? How safe is ESK-001 in…
- Trial name
- ONWARD1 (NCT06586112)
- Testing
- Envudeucitinib, Apremilast
- Where
- 156 sites in United States, Australia and 8 more
- Volunteers
- 912 people
- Sponsor
- Alumis Inc
Moderate to Severe Psoriasis
Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis
To compare the efficacy of ETN 50mg twice weekly for 12 weeks followed by reduction to a maintenance dose of 25mg twice weekly at week 24 with that of combination of ETN 25 mg Twice Weekly plus Acitretin 10mg BID at week 24 in…
- Trial name
- NCT00936065
- Testing
- Etanercept, Etanercept + Acitretin, Acitretin
- Where
- 10 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Pfizer
Plaque-type Psoriasis
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis
The study will assess the safety and efficacy of intravenous (10mg/kg) and subcutaneous (300mg) secukinumab in moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab.
- Trial name
- STATURE (NCT01412944)
- Testing
- secukinumab 150mg, secukinumab 10mg/kg i.v. regimen
- Where
- 27 sites in United States, Austria and 6 more
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Plaque Psoriasis
Documentation of Humira in Psoriasis Patients in Routine Clinical Practice
Safety and Effectiveness of adalimumab (Humira) in Psoriasis Patients in Routine Clinical Practice.
- Trial name
- LOTOS (NCT01077232)
- Where
- 641 sites in Germany
- Volunteers
- 5,442 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Phase III, Multicenter Study of the Efficacy and Safety of Adalimumab Treatment in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT00237887
- Testing
- adalimumab
- Volunteers
- 1,212 people
- Sponsor
- Abbott
Psoriasis
A Registry of Patients With Moderate to Severe Plaque Psoriasis
The main purpose of the current study will be to provide real - world evidence regarding the safety and effectiveness of secukinumab in the management of patients with moderate to severe chronic plaque psoriasis.
- Trial name
- PURE (NCT02786186)
- Testing
- Secikinumab
- Where
- 13 sites in Canada
- Volunteers
- 2,376 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis
Psoriasis is a chronic disease characterized by marked inflammation and thickening of the skin that results in thick, scaly skin plaques.
- Trial name
- NCT05044234
- Testing
- Cedirogant
- Where
- 53 sites in United States, Canada and 1 more
- Volunteers
- 156 people
- Sponsor
- AbbVie
Generalized Pustular Psoriasis
Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis
To evaluate efficacy, safety, and tolerability of spesolimab (BI 655130) compared to placebo in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.
- Trial name
- NCT03782792
- Testing
- Spesolimab
- Where
- 37 sites in United States, China and 10 more
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Psoriasis
A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)
This is a two-part study. The purpose of the pilot study (Part 1) is to optimize the acquisition, handling and shipping procedure for skin biopsies obtained from participants with plaque psoriasis.
- Trial name
- NCT01276847
- Testing
- Ustekinumab, Etanercept
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
This double-blind, placebo-controlled study will be conducted at 5 study centers in the United States. Approximately 30 subjects with moderate to severe plaque-type psoriasis will take part.
- Trial name
- NCT01154101
- Testing
- SRT2104
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sirtris, a GSK Company
Moderate to Severe Chronic Plaque Psoriasis
A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a phase II, randomised, double-blind, placebo-controlled, multiple-dose, multi-center study of AbGn-168H in subjects with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT02223039
- Testing
- AbGn-168H
- Where
- 15 sites in United States
- Volunteers
- 50 people
- Sponsor
- AbGenomics B.V Taiwan Branch
Moderate to Severe Chronic Plaque Psoriasis
Post Marketing Observational Study on Venezuelan Patients With Psoriasis
The aim of this study is to obtain Venezuelan data of clinical effectiveness, impact in the HRQoL, work productivity and activity impairment in patients with psoriasis using adalimumab.
- Trial name
- NCT01758705
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis Vulgaris
A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris
The primary objective is to assess the safety and tolerability of 200 mg of belumosudil administered orally once daily for 28 days.
- Trial name
- NCT02106195
- Testing
- Belumosudil
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Kadmon Corporation, LLC